```
=> RAC and MELK
L1            0 FILE AGRICOLA
L2            0 FILE BIOTECHNO
L3            0 FILE CONFSCI
L4            0 FILE HEALSAFE
L5            0 FILE LIFESCI
L6            0 FILE PASCAL

TOTAL FOR ALL FILES
L7            0 RAC AND MELK

=> (maternal embryonic leucine zipper kinase)
L8            3 FILE AGRICOLA
L9            1 FILE BIOTECHNO
L10           2 FILE CONFSCI
L11           0 FILE HEALSAFE
L12           7 FILE LIFESCI
L13           2 FILE PASCAL

TOTAL FOR ALL FILES
L14          15 (MATERNAL EMBRYONIC LEUCINE ZIPPER KINASE)

=> l14 and RAC
L15           0 FILE AGRICOLA
L16           0 FILE BIOTECHNO
L17           0 FILE CONFSCI
L18           0 FILE HEALSAFE
L19           0 FILE LIFESCI
L20           0 FILE PASCAL

TOTAL FOR ALL FILES
L21           0 L14 AND RAC

=> l14 and (RAC pathway)
L22           0 FILE AGRICOLA
L23           0 FILE BIOTECHNO
L24           0 FILE CONFSCI
L25           0 FILE HEALSAFE
L26           0 FILE LIFESCI
L27           0 FILE PASCAL

TOTAL FOR ALL FILES
L28           0 L14 AND (RAC PATHWAY)

=> RAC pathway
L29           3 FILE AGRICOLA
L30          17 FILE BIOTECHNO
L31           0 FILE CONFSCI
L32           0 FILE HEALSAFE
L33          36 FILE LIFESCI
L34          15 FILE PASCAL

TOTAL FOR ALL FILES
L35          71 RAC PATHWAY

=> l35 and kinase
L36           1 FILE AGRICOLA
L37          11 FILE BIOTECHNO
L38           0 FILE CONFSCI
L39           0 FILE HEALSAFE
L40          22 FILE LIFESCI
```

```
L41           9 FILE PASCAL

TOTAL FOR ALL FILES
L42          43 L35 AND KINASE

=> l42 and melk
L43           0 FILE AGRICOLA
L44           0 FILE BIOTECHNO
L45           0 FILE CONFSCI
L46           0 FILE HEALSAFE
L47           0 FILE LIFESCI
L48           0 FILE PASCAL

TOTAL FOR ALL FILES
L49           0 L42 AND MELK

=> l42 and leucine
L50           0 FILE AGRICOLA
L51           0 FILE BIOTECHNO
L52           0 FILE CONFSCI
L53           0 FILE HEALSAFE
L54           0 FILE LIFESCI
L55           0 FILE PASCAL

TOTAL FOR ALL FILES
L56           0 L42 AND LEUCINE

=> file .jacob
COST IN U.S. DOLLARS                            SINCE FILE      TOTAL
                                                     ENTRY    SESSION
FULL ESTIMATED COST                                   7.77       7.99

FILE 'CAPLUS' ENTERED AT 15:41:35 ON 24 FEB 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'BIOSIS' ENTERED AT 15:41:35 ON 24 FEB 2010
Copyright (c) 2010 The Thomson Corporation

FILE 'MEDLINE' ENTERED AT 15:41:35 ON 24 FEB 2010

FILE 'EMBASE' ENTERED AT 15:41:35 ON 24 FEB 2010
Copyright (c) 2010 Elsevier B.V. All rights reserved.

FILE 'USPATFULL' ENTERED AT 15:41:35 ON 24 FEB 2010
CA INDEXING COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

=> melk and rac
L57          11 FILE CAPLUS
L58           0 FILE BIOSIS
L59           0 FILE MEDLINE
L60           0 FILE EMBASE
L61          39 FILE USPATFULL

TOTAL FOR ALL FILES
L62          50 MELK AND RAC

=> dup rem
ENTER L# LIST OR (END):157
PROCESSING COMPLETED FOR L57
```

```
L63          11 DUP REM L57 (0 DUPLICATES REMOVED)

=> l63 and kinase
L64          11 S L63
L65          11 FILE CAPLUS
L66           0 S L63
L67           0 FILE BIOSIS
L68           0 S L63
L69           0 FILE MEDLINE
L70           0 S L63
L71           0 FILE EMBASE
L72           0 S L63
L73           0 FILE USPATFULL

TOTAL FOR ALL FILES
L74          11 L63 AND KINASE

=> d l74 ibib abs total

L74  ANSWER 1 OF 11  CAPLUS  COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER:         2009:738937  CAPLUS
DOCUMENT NUMBER:          151:70264
TITLE:                    Stromal gene signatures for predicting the efficacy of
                          cancer therapy
INVENTOR(S):              Farmer, Pierre; Delorenzi, Mauro; Bonnefoi, Herve;
                          Iggo, Richard
PATENT ASSIGNEE(S):       Ecole Polytechnique Federale de Lausanne, Switz.
SOURCE:                   PCT Int. Appl., 66pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.        DATE
     ---------------      ----   --------    --------------------   --------
     WO 2009074968         A2    20090618    WO 2008-IB55252        20081212
     WO 2009074968         A3    20090924
         W:  AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
             CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
             FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
             KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
             ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
             PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
             TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
         RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
             IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
             TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
             TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
             AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
PRIORITY APPLN. INFO.:                       US 2007-996961P     P  20071212
AB   The present invention relates to a method and a kit for predicting the
     efficacy of cancer therapy in a subject who has undergone or is undergoing
     chemotherapy treatment for cancer.  The Applicants have identified stromal
     gene signatures that predict poor pathol. response to anthracycline-based
     neo-adjuvant chemotherapy in two independent datasets.  These signatures
     were shown to be a reflection of the activation state of the tumor stroma.
     The Applicants identified stromal genes signature that influences the
     response of cancers to anthracycline-based neo-adjuvant chemotherapy.  The
     Applicants have identified several specific combinations of stromal genes,
     which are part of the stromal metagene and which are biomarkers for
```

chemosensitivity of cancer subjects to the anthracycline-based neo-adjuvant chemotherapy. Results show a significant association between response to fluorouracil (5-FU) and the stromal's metagene scores AUC 0.77; p = 0.032. The stromal signature predicts response to fluorouracil in rectal cancer patients.

L74 ANSWER 2 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:599273 CAPLUS
DOCUMENT NUMBER: 150:556980
TITLE: Gene expression profile in human liver cells treated by benzo[a]anthracene and the use of the genes as biomarker for monitoring benzo[a]anthracene pollution in environment
INVENTOR(S): Ryu, Jae Cheon; Kim, Yeon Jeong; Jeon, Hui Gyeong; Song, Mi Gyeong
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, 50pp.
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2009048057	A	20090513	KR 2007-114257	20071109

PRIORITY APPLN. INFO.: KR 2007-114257 20071109
AB This invention provides gene expression profile in human liver cells treated by benzo[a]anthracene. The change of expression level of the genes was evaluated by comparing the gene expression level in HEp-2 cells and that in the normal liver cells. The genes provided in this invention can be used as biomarkers for monitoring benzo[a]anthracene in environment and investigating the mechanism of toxicity induced by benzo[a]anthracene.

L74 ANSWER 3 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2008:1547187 CAPLUS
DOCUMENT NUMBER: 150:141906
TITLE: Gene expression profile in HUVEC induced by treatment of doxorubicin and its use for screening drugs inducing cardiotoxicity
INVENTOR(S): Ryu, Jae Cheon; Kim, Yeon Jeong; Song, Mi; Lee, Ha Eun
PATENT ASSIGNEE(S): Korea Institute of Science and Technology, S. Korea
SOURCE: Repub. Korean Kongkae Taeho Kongbo, 32pp.
CODEN: KRXXA7
DOCUMENT TYPE: Patent
LANGUAGE: Korean
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
KR 2008112764	A	20081226	KR 2007-61573	20070622
KR 901127	B1	20090608		

PRIORITY APPLN. INFO.: KR 2007-61573 20070622
AB This invention provides gene expression profile in HUVEC induced by treatment of doxorubicin treatment. The marker genes are up-regulated or down-regulated in expression after doxorubicin treatment, and screened via a DNA microarray chip. The marker genes can be used for monitoring and judging drugs or chems. with cardiotoxicity, and analyzing the reasons causing cardiotoxicity.

L74 ANSWER 4 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:1251815 CAPLUS
DOCUMENT NUMBER: 146:26324
TITLE: Early diagnosis of transplant rejection by analysis of gene expression profiles
INVENTOR(S): Halloran, Philip F.
PATENT ASSIGNEE(S): The Governors of the University of Alberta, Can.
SOURCE: PCT Int. Appl., 168pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006125301	A1	20061130	WO 2006-CA792	20060516
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20060269949	A1	20061130	US 2006-434711	20060515
US 7666596	B2	20100223		

PRIORITY APPLN. INFO.: US 2005-683737P P 20050523
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB This document relates to methods and materials involved in detecting tissue rejection (e.g., organ rejection). For example, this document relates to methods and materials involved in the early detection of kidney tissue rejection. Genes showing changes in levels of transcription during the rejection of kidney transplants are identified for use in the early diagnosis of transplant rejection. Two major classes of transcript are identified, one group associated directly with the rejection process and a group induced by interferon γ.
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2006:817670 CAPLUS
DOCUMENT NUMBER: 145:246599
TITLE: Genes showing changes in levels of expression in bladder cancer and their use in diagnosis and the development of antitumor agents
INVENTOR(S): Nakamura, Yusuke; Katagiri, Toyomasa; Nakatsuru, Shuichi
PATENT ASSIGNEE(S): Oncotherapy Science, Inc., Japan; The University of Tokyo
SOURCE: PCT Int. Appl., 331pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006085684	A2	20060817	WO 2006-JP302684	20060209
WO 2006085684	A9	20061019		
WO 2006085684	A3	20070329		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1856278	A2	20071121	EP 2006-713825	20060209
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
JP 2008532477	T	20080821	JP 2007-535933	20060209
EP 2011885	A2	20090107	EP 2008-13455	20060209
EP 2011885	A3	20090624		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101175862	A	20080507	CN 2006-80011580	20071010
US 20090175844	A1	20090709	US 2008-815850	20081120

PRIORITY APPLN. INFO.:	US 2005-652318P	P	20050210
	US 2005-703225P	P	20050727
	EP 2006-713825	A3	20060209
	WO 2006-JP302684	W	20060209

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB Genes that show changes in levels of expression in bladder cancer tissue compared to normal bladder are identified for use in diagnosis and as targets for therapy. The present invention further provides means for predicting and preventing bladder cancer metastasis using BLC-associated genes having unique altered expression patterns in bladder cancer cells with lymph-node metastasis. Finally, the present invention provides methods of screening for therapeutic agents useful in the treatment of bladder cancer, methods of treating bladder cancer and method for vaccinating a subject against bladder cancer. The genes and polypeptides encoded by the genes can be used, for example, in the diagnosis of bladder cancers, as target mols. for developing drugs against the disease, and for attenuating cell growth of bladder cancer. Anal. of normal and neoplastic bladder tissue from 33 patients using an array containing 27,648 cDNAs identified 394 genes upregulated in bladder cancer and 1,272 that were down-regulated. Three genes: C2093 (MPHOSPH1); C6055 (MGC30342), and B5680N (DEPDC1), were highly informative and predictive and tested as targets for siRNA therapy. SiRNAs against all three genes inhibited the growth of bladder cancer cell lines in culture.

OS.CITING REF COUNT:	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 6 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER:	2005:1311496 CAPLUS
DOCUMENT NUMBER:	144:49649
TITLE:	Association of gene expression profiles with asthma in

peripheral blood cells
INVENTOR(S): Kachalsky, Sylvia G.; Horev, Guy
PATENT ASSIGNEE(S): Linkagene Ltd., Israel
SOURCE: PCT Int. Appl., 74 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005118403	A2	20051215	WO 2005-IL590	20050605
WO 2005118403	A3	20090423		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AP, EA, EP, OA				
EP 1758792	A2	20070307	EP 2005-753551	20050605
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, LV, MK, YU				
US 20070148676	A1	20070628	US 2006-633063	20061201

PRIORITY APPLN. INFO.: US 2004-576599P P 20040604
WO 2005-IL590 W 20050605
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention relates to methods of identifying biomarkers for disease, which comprise measuring gene expression levels in subpopulations of blood cells obtained from subjects of closed populations. Particularly, the present invention relates to methods of diagnosing, monitoring and prognosing diseases comprising determining expression levels of disease-specific genes. Thus, a library of about 41,500 cDNA clones derived from the I.M.A.G.E consortium was printed in microarrays comprising the whole transcriptome and used to screen RNA isolated from leukocytes from a Cochin Jewish population known as susceptible to high occurrences of asthma. Comparison of expression profiles from asthma and non-asthma individuals identified 783 biomarker transcripts for asthma.
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L74 ANSWER 7 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:1020555 CAPLUS
DOCUMENT NUMBER: 143:320266
TITLE: Genes with differential expression profile between human dental pulp stem cells and mesenchymal stem cells and use for regenerating tooth germ
INVENTOR(S): Ueda, Minoru; Yamada, Yoichi
PATENT ASSIGNEE(S): Hitachi Medical Corp., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 246 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005253442	A	20050922	JP 2004-111582	20040309

PRIORITY APPLN. INFO.: JP 2004-111582 20040309

AB The present invention relates to a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells, as well as a method for regenerating tooth germ using these genes. According to the present invention, the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cell were revealed, and a group of genes whose expression profile are different between human dental pulp stem cells and mesenchymal stem cells was identified. By utilizing the groups of the genes of the present invention together with the dental pulp stem cells and mesenchymal stem cells, hard tissue such as tooth germ, dental pulp, dentin or bone can be regenerated. The present inventors investigated the gene expression profiles and cluster anal. between human dental pulp stem cells (hDPSCs) and mesenchymal stem cells (hMSCs) as representative populations of odontoprogenitor and osteoprogenitor cells, resp. At first, the present inventors confirmed the differential expression of Alkaline phosphatase (ALP) activity, Dentin matrix protein 1 (DMP 1), Dentin phosphosialoprotein (DSPP) using by real time reverse-transcriptase polymerase chain reaction (RT-PCR) in total RNA from primary cultures. The number of genes in hDPSCs(I) that were up-regulated by 2>-fold, compared to hMSCs, was 614 (Table, IV). On the other band, the number of genes down regulated by <2-fold in hDPSCs (I) was 296 (Table III, IV).

L74 ANSWER 8 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2005:158510 CAPLUS
DOCUMENT NUMBER: 142:255807
TITLE: Maternal embryonic leucine zipper kinases (MELKs) as modifiers of the RAC pathway and uses thereof in diagnosis, therapy and drug screening
INVENTOR(S): Kadyk, Lisa; Francis, George Ross; Heuer, Timothy S.; Lickteig, Kim
PATENT ASSIGNEE(S): Exelixis, Inc., USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005016279	A2	20050224	WO 2004-US26231	20040812
WO 2005016279	A3	20050728		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,

SN, TD, TG

AU 2004264936	A1	20050224	AU 2004-264936	20040812
CA 2535808	A1	20050224	CA 2004-2535808	20040812
EP 1651956	A2	20060503	EP 2004-780986	20040812
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2007502115	T	20070208	JP 2006-523383	20040812
US 20080293044	A1	20081127	US 2006-567765	20060914
PRIORITY APPLN. INFO.:			US 2003-495193P	P 20030814
			WO 2004-US26231	W 20040812

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention has designed a dominant loss of function screen to identify genes that interact with the RAC in C. elegans. Maternal embryonic leucine zipper kinase (MELK) gene was identified as a modifier of the RAC pathway. Accordingly, vertebrate orthologs of these modifiers, and preferably the human orthologs, maternal embryonic leucine zipper kinase (MELK) genes are attractive drag targets for the treatment of pathologies associated with a defective RAC signaling pathway, such as cancer. The invention also provides methods for utilizing these RAC modifier genes and polypeptides to identify candidate therapeutic agents that can be used in the treatment of disorders associated with defective RAC function.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 9 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:718550 CAPLUS
DOCUMENT NUMBER: 141:241509
TITLE: Differentially expressed nucleic acids that correlate with KSP expression and their use as markers for diagnosis, classification, and treatment of cancer
INVENTOR(S): Huang, Pearl S.; Jackson, Jeffrey R.
PATENT ASSIGNEE(S): SmithKline Beecham Corporation, USA
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004074301	A2	20040902	WO 2004-US4276	20040213
WO 2004074301	A3	20060504		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1620449	A2	20060201	EP 2004-711130	20040213
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006521794	T	20060928	JP 2006-503555	20040213

US 20070015154 A1 20070118 US 2006-544704 20060526
PRIORITY APPLN. INFO.: US 2003-447842P P 20030214
WO 2004-US4276 W 20040213
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
AB The present invention is based on the discovery of differentially expressed nucleic acid markers that correlate pos. or neg. with expression levels of the mitotic kinesin KSP (kinesin-like 1, also termed HsEgS). Because KSP expression is increased in certain tumor types but not others, the markers can be used as surrogates for KSP (or alternatively in combination with KSP) to classify tumors into different general classes or types. The Human U133 chip set from Affymetrix comprising .apprx.44,000 gene probes was used to show that breast infiltrating carcinomas fall into 3 classes. Tumors with normal KSP levels showed significant up-regulation of signal transduction genes, but significant down-regulation of cell cycle genes, whereas most tumors with high levels of KSP exhibited down-regulation of signal transduction genes and up-regulation of cell cycle genes. A third group of tumors having high KSP levels showed up-regulation of both signal transduction genes and cell cycle genes. Thus, a variety of classification, screening, diagnostic, and treatment methods are provided based upon these differentially expressed nucleic acids. Devices and kits for performing such methods are also disclosed.
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L74 ANSWER 10 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:836498 CAPLUS
DOCUMENT NUMBER: 139:336483
TITLE: Gene expression profiles for diagnostic and prognostic grading of breast cancer and for drug screening
INVENTOR(S): Erlander, Mark G.; Ma, Xiao-Jun; Sgroi, Dennis C.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 36 pp., Cont.-in-part of U.S. Ser. No. 28,018.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030198972	A1	20031023	US 2002-211015	20020801
US 20040002067	A1	20040101	US 2001-28018	20011221
US 20030236632	A1	20031225	US 2002-282596	20021028
WO 2003060164	A1	20030724	WO 2002-US41216	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
WO 2003060470	A2	20030724	WO 2002-US41347	20021220
WO 2003060470	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,				

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2002358279	A1	20030730	AU 2002-358279	20021220
AU 2002360769	A1	20030730	AU 2002-360769	20021220
US 20060263806	A1	20061123	US 2006-381353	20060502
US 20060234287	A1	20061019	US 2006-426572	20060626
US 20090092973	A1	20090409	US 2007-946835	20071128
PRIORITY APPLN. INFO.:			US 2001-28018 A2	20011221
			US 2002-211015 A2	20020801
			US 2002-282596 A	20021028
			WO 2002-US41216 W	20021220
			WO 2002-US41347 W	20021220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to the identification and use of gene expression patterns (or profiles or "signatures") which are correlated with (and thus able to discriminate between) cells in various stages and/or grades of breast cancer. Broadly defined, these stages are non-malignant vs. malignant, but may also be viewed as normal vs. atypical (optionally including reactive and pre-neoplastic) vs. cancerous. Another definition of the stages is normal vs. precancerous (e.g. atypical ductal hyperplasia or atypical lobular hyperplasia) vs. cancerous (e.g., carcinoma in situ such as ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)) vs. invasive (e.g. carcinomas such as invasive ductal carcinoma and/or invasive lobular carcinoma). The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of mol. criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. The gene CRIP1 is especially prominent and thus may be a potential biomarker for the detection of breast cancer including the pre-malignant stage of atypical ductal hyperplasia. The epithelium-specific transcription factor ELF5 is also noteworthy since it maps to chromosome 11p13-15, a region subject to frequent loss of heterzygosity and rearrangement in multiple carcinoma including breast cancer.

L74 ANSWER 11 OF 11 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:571236 CAPLUS
DOCUMENT NUMBER: 139:112797
TITLE: Gene expression profiles for diagnostic and prognostic grading of breast cancer
INVENTOR(S): Erlander, Mark G.; Ma, Xiao-Jun; Sgroi, Dennis C.
PATENT ASSIGNEE(S): Arcturus Engineering, Inc., USA; The General Hospital Corporation
SOURCE: PCT Int. Appl., 264 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003060470	A2	20030724	WO 2002-US41347	20021220
WO 2003060470	A3	20031113		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ,
CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 20040002067	A1	20040101	US 2001-28018	20011221
US 20030198972	A1	20031023	US 2002-211015	20020801
AU 2002360769	A1	20030730	AU 2002-360769	20021220
PRIORITY APPLN. INFO.:			US 2001-28018 A	20011221
			US 2002-211015 A	20020801
			WO 2002-US41347 W	20021220

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB This invention relates to the identification and use of gene expression patterns (or profiles or "signatures") which are correlated with (and thus able to discriminate between) cells in various stages and/or grades of breast cancer. Broadly defined, these stages are non-malignant vs. malignant, but may also be viewed as normal vs. atypical (optionally including reactive and pre-neoplastic) vs. cancerous. Another definition of the stages is normal vs. precancerous (e.g. atypical ductal hyperplasia or atypical lobular hyperplasia) vs. cancerous (e.g., carcinoma in situ such as ductal carcinoma in situ (DCIS) and/or lobular carcinoma in situ (LCIS)) vs. invasive (e.g. carcinomas such as invasive ductal carcinoma and/or invasive lobular carcinoma). The signature profiles are identified based upon multiple sampling of reference breast tissue samples from independent cases of breast cancer and provide a reliable set of mol. criteria for identification of cells as being in one or more particular stages and/or grades of breast cancer. The gene CRIP1 is especially prominent and thus may be a potential biomarker for the detection of breast cancer including the pre-malignant stage of atypical ductal hyperplasia. The epithelium-specific transcription factor ELF5 is also noteworthy since it maps to chromosome 11p13-15, a region subject to frequent loss of heterzygosity and rearrangement in multiple carcinoma including breast cancer.

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

=>